The study, involving researchers in the Hope Clinical Trials Facility at Leicester’s Hospitals and the University of Leicester, consisted of one hundred and twenty participants over eleven sites.
Nabriva Therapeutics announced positive topline results from its Lefamulin Evaluation Against Pneumonia (LEAP 2) clinical trial, the second of two global, pivotal Phase 3 clinical trials of lefamulin.